OTC: MLLCF - Molecular Partners AG

Altı ay boyunca karlılık: -58.48%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı Molecular Partners AG


Şirket hakkında Molecular Partners AG

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.

daha fazla ayrıntı
The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins. It also develops MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor (VEGF)and hepatocyte growth factor. Molecular Partners AG has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.molecularpartners.com
Цена ао 4.1
Günlük fiyat değişimi: 0% (4.11)
Haftalık fiyat değişimi: -17.8% (5)
Aylık fiyat değişimi: -9.27% (4.53)
3 ayda fiyat değişimi: -30.22% (5.89)
Altı ayda fiyat değişimi: -58.48% (9.9)
Yıllık fiyat değişimi: -4.42% (4.3)
3 yılda fiyat değişimi: -77.72% (18.45)
5 yılda fiyat değişimi: 0% (4.11)
10 yılda fiyat değişimi: 0% (4.11)
Yılbaşından bu yana fiyat değişimi: -17.8% (5)

Hafife alma

İsim Anlam Seviye
P/S 15.89 1
P/BV 0.7535 9
P/E 1.56 10
EV/EBITDA 0.7215 10
Toplam: 7.5

Yeterlik

İsim Anlam Seviye
ROA, % -37.12 0
ROE, % -41.73 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 0.0057

Görev

İsim Anlam Seviye
Debt/EBITDA -0.0519 10
Toplam: 9

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % -64.57 0
karlılık Ebitda, % 86.31 9
karlılık EPS, % 14.59 3
Toplam: 6



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Patrick Amstutz Ph.D. Co-Founder, CEO, Member of Management Board & Director 735.02k 1975 (50 yıllar)
Dr. Michael Tobias Stumpp Ph.D. Co-Founder, Executive VP of Projects & Member of Management Board N/A 1972 (53 yıl)
Mr. Robert Hendriks Senior VP of Finance N/A
Mr. Alexander Zurcher COO & Member of Management Board N/A 1975 (50 yıllar)
Ms. Renate Gloggner Executive VP of People & Community and Member of Management Board N/A 1970 (55 yıllar)
Mr. Daniel Steiner Ph.D. Senior Vice President of Research & Technology N/A
Mr. Seth D. Lewis Senior Vice President of Investor Relations, Communications & Strategy N/A
Mr. Michael Pitzner General Counsel, Compliance Officer, Senior VP Legal & Business Development N/A
Dr. Pamela A. Trail Ph.D. Strategic Consultant N/A 1956 (69 yıllar)
Ms. Anne Goubier D.V.M., Ph.D. Senior Vice President of Research & Early Development N/A

Adres: Switzerland, Schlieren, Wagistrasse 14 - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.molecularpartners.com